Dr. Martinez joined BioGX in 2015. Dr. Martinez is responsible for Business Development and Scientific Affairs, expanding our portfolio of IVD products, managing the global technical support efforts of all molecular diagnostic products, and manages a team of scientists responsible for product and technology innovation in conjunction with existing corporate partnerships. Dr. Martinez has over 20 years of experience in molecular biology. Prior to joining BioGX, Dr. Martinez held research positions focusing on cancer cell biology at Albany Medical College, microbial community dynamics at The Georgia Institute of Technology and microbial physiology at The University of Alabama. Dr. Martinez holds a BA in Biology from Boston University and a Ph.D. in Microbiology from The Georgia Institute of Technology.
Mr. Green joined BioGX as a Controller in 2020. He has 30+ years of leadership experience in accounting across diverse industries, including healthcare, water utility management, waste management, mineral extraction, and cash handling. At BioGX, Mr. Green is responsible for managing finance and purchasing departments. He has a BS degree in Accounting from The University of Alabama, and he is a Certified Public Accountant (inactive).
Dr. Shazi Iqbal is a Co-Founder of BioGX and served as its CEO from 2011 to June 2024. Now, as a Venture Partner, he leads M&A and strategic investment opportunities to enable innovation partnerships. Dr. Iqbal has over 25+ years of experience in building healthcare startups into profitable growth companies. He holds a Ph.D. in Biology (Neuroscience), two M.S. degrees in Biochemistry & Biotechnology, and several patents and publications.
Targets |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bacteria | Viruses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Dr. Shahin Iqbal is the President and Chief Operating Officer at BioGX. He has over 25 years of experience in clinical molecular diagnostics. Before joining BioGX, Dr. Iqbal led the Abbott Diagnostics Global Service & Support specifically for informatics, core lab automation, immunoassay and clinical chemistry systems. He was also responsible for design and development of FISH automation systems at Abbott Molecular. He is the recipient of the President awards and multiple service & innovation awards at Abbott. Dr. Iqbal holds multiple patents on optical sensors, automation systems development, RFID applications and robotics for system dispensing. Prior to joining Abbott, Dr. Iqbal was Head of operations, quality & regulatory, systems development and manufacturing of IHC systems at BioGenex in California. Dr. Iqbal has an MBA and Ph.D as well as a Masters in Electrical Engineering degree from the University of Texas in San Antonio.
Mr. Blackstone joined BioGX in 2007. He has served at BioGX in various senior R&D and quality management roles prior to his current position as VP of Research & Development. Mr. Blackstone has designed and directed the development of over 100 multiplex real time PCR products in the fields of food safety, water quality, pharma QC, and clinical diagnostics. Mr. Blackstone previously served for eight years at the US Food and Drug Administration and as a Commissioned Research Officer in the US Public Health Service Commissioned Corps where he achieved the rank of Lieutenant Commander. George Blackstone received his Master of Science degree from Louisiana State University.
Mr. Hughes joined BioGX in 2015. Prior to joining BioGX, Mr. Hughes led efforts for a diverse range of companies with the development and implementation of certified quality management systems ranging from data storage devices with SONY Corporation, security & detention devices with Norment Security Group, textile manufacturing with Twitchell Corporation, combat vehicle manufacturing with General Dynamics, and therapeutic medical devices with Steris Corporation. Christopher has a BSE from Auburn University and an MBA from Troy State University.
If you are contacting us because you have received a phone call offering genetic testing services, with the caller requesting personal health information and personal identification numbers (such as Medicare Card numbers), please know that we are NOT responsible for such calls.
We, BioGX, Inc., (registered trademark “BioGX”) with offices in Birmingham, AL, Dallas, TX, and Amsterdam, The Netherlands, are a diagnostic test manufacturer and not a testing laboratory, and we are not in any way affiliated with such callers. We do not know who is making these calls.
UNDER NO CIRCUMSTANCES BIOGX WOULD EVER CONTACT INDIVIDUALS TO OFFER GENETIC TESTING SERVICES OR REQUEST PERSONAL INFORMATION OF ANY KIND.
This Fact Sheet informs you of the significant known and potential risks and benefits of the use of the BioGX Xfree™ COVID-19 Direct RT-PCR.
The BioGX Xfree™ COVID-19 Direct RT-PCR is validated for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider.
QuantStudio™ 5 Direct Sample Run File
QuantStudio™ 5 Direct Sample PDF
CFX96 Touch™ Direct Sample Run File 1
CFX96 Touch™ Direct Sample Run File 2
CFX96 Touch™ Direct Sample PDF
Dr. Vickery founded BioGX in 2007 and served as President and CEO until 2011. Prior to founding BioGX, Dr. Vickery worked in sales and as a technical consultant at Cepheid. Prior to Cepheid, Dr. Vickery worked at the FDA as a University of Maryland JIFSAN postdoctoral fellow at the University of Maryland, and later served as the Lead for Molecular Methods Development at the U.S. FDA Gulf Coast Seafood Laboratory. He holds multiple patents in biotechnology, has authored or co-authored many publications, and has extensive experience in gene expression analysis, and in the design and development of rapid multiplex molecular tests for microbial and viral detection. Dr. Vickery holds a B.S. degree in Physics and both M.S. and Ph.D. degrees in Biology (molecular biology and molecular genetics focus – both prokaryotic and eukaryotic). Prior to entering graduate school, Dr. Vickery worked as an executive in the lowbed trailer industry for almost 10 years, pioneering the sale of American made heavy equipment transport trailers into China (ROC) and Japan during his tenure in the industry, and resupplying the oilfields of Kuwait with specialized trailers after the Gulf War.
BioGX Celebrates Success Of Global Partnership Initiative, Announces New Distribution Partnerships In EMEA And Asia-Pacific
Amsterdam, The Netherlands, 01 November 2018 – Amsterdam-based BioGX B.V., a subsidiary of Birmingham, Alabama based molecular diagnostics company BioGX, today announced several new distribution partnerships in the EMEA and Asia-Pacific as it continues to expand its global presence.
BioGX Launches 5 New CE Mark IVD Tests, Expands Number Of Sexual Health Panels
Amsterdam, The Netherlands, 23 October 2018 – BioGX B.V. recently released 5 new sexual health CE Mark IVD tests, expanding BioGX’s CE-IVD menu to a total of 21 multiplex panels, with additional test panels to be released before the end of 2018.
BioGX Launches Six CE-Mark Tests For Meningitis And Antibiotic Resistance
Amsterdam, The Netherlands, 24 May 2018 – BioGX B.V. continues its *BD MAX menu expansion with the launch of six additional CE-Mark infectious disease tests on Becton, Dickinson and Company’s BD MAX Sample-to-Answer platform. This brings the company’s CE-Mark menu for the BD MAX to eleven tests, with an additional ten planned for the second half […]
BioGX And Launch Diagnostics Announce Distribution Partnership For U.K. And Ireland
BIRMINGHAM, Ala., Feb. 8, 2018 /PRNewswire/ — BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX’s Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics.
BioGX BV And AxonLab AG Announce Distribution Partnership
BIRMINGHAM, Ala., Feb. 6, 2018 /PRNewswire/ — BioGX continues to expand its international presence with the announcement of a new strategic partnership between BioGX’s Amsterdam-based European subsidiary and Switzerland-based distributor, AxonLab AG.
BioGX Launches Four CE-Marked IVD Assays At The European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)
VIENNA, AUSTRIA, April 24, 2017 /PRNewswire/ — BioGX, a Birmingham Alabama based molecular diagnostics company, announced the launch of four additional CE-IVD infectious disease tests at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), reflecting the inspiring vision of ECCMID: “Managing Infections, Promoting Science”. BioGX has developed an extensive line of multiplex tests […]
Announcing The Establishment Of BioGX EU
BIRMINGHAM, Ala., April 21, 2017 /PRNewswire/ — BioGX, a developer and manufacturer of molecular diagnostics CE-IVD tests has announced the establishment of European operations based in Amsterdam, Netherlands.
BioGX Sample-Ready™ Technology Selected By NASA For Genetic Analysis Aboard The International Space Station
BIRMINGHAM, Ala., November 10, 2016 — BioGX announced its Sample-Ready™ lyophilized qPCR technology was selected by the NASA WetLab-2 program to conduct genetic analysis aboard the International Space Station (ISS). BioGX core technology enables real-time PCR based scientific studies in the microgravity environment of the ISS.
BioGX Receives CE-IVD Mark For Influenza A, B And Respiratory Syncytial Virus Assay On The BD MAX System
BioGX announced it has received CE-IVD marking for its Flu A, Flu B, RSV automated test on Becton, Dickinson and Company’s (BD) BD MAXTM system for detection of Influenza A, B and Respiratory Syncytial Virus (RSV). The test is intended to simultaneously detect the presence of Flu A, Flu B and RSV RNA present in […]